ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 36970205

Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer.

Feng J and 10 others. Acta Pharm Sin B, 2023. Cited by 41 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer. Papers, record 36970205. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36970205

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer.
PubMed
Journal
Acta Pharm Sin B
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
41
iCite
Relative citation ratio, by iCite
3.43
iCite
Revised in PubMed
2023-03-28
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Feng JJuanjuan
2Lian ZZhengke
3Xia XXinting
4Lu YYue
5Hu KKewen
6Zhang YYunpeng
7Liu YYanan
8Hu LLongmiao
9Yuan KKun
10Sun ZZhenliang

1 to 10 of 11Source PubMed

See all 11 authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References61

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131,439,581A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma.Clin Cancer Res2019https://conductscience.org/library/papers/31439581PubMed
224,768,991ERK-mediated phosphorylation of TFAM downregulates mitochondrial transcription: implications for Parkinson's disease.Mitochondrion2014https://conductscience.org/library/papers/24768991PubMed
319,401,449PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.Cancer Res2009https://conductscience.org/library/papers/19401449PubMed
434,613,810Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer.Sci Transl Med2021https://conductscience.org/library/papers/34613810PubMed
527,338,794A combinatorial strategy for treating KRAS-mutant lung cancer.Nature2016https://conductscience.org/library/papers/27338794PubMed
626,365,176MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells.Cell Metab2015https://conductscience.org/library/papers/26365176PubMed
722,899,010Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells.Genes Dev2012https://conductscience.org/library/papers/22899010PubMed
825,607,840Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation.J Clin Invest2015https://conductscience.org/library/papers/25607840PubMed
922,409,661Pyruvate dehydrogenase deficiency and the brain.Dev Med Child Neurol2012https://conductscience.org/library/papers/22409661PubMed
1025,119,024Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.Nature2014https://conductscience.org/library/papers/25119024PubMed

1 to 10 of 61

See all 61 references

Cited by35

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 41 citations.

PMIDTitleJournalYearIn PapersSource
42,979,327Concurrent loss of RB1 facilitates EGFR-TKI resistance in EGFR-mutant lung cancer by modulating histone crotonylation.Acta Pharm Sin B2026https://conductscience.org/library/papers/42979327PubMed
42,952,304High Level of Component C1q Binding Protein (C1QBP) is Associated With Poor Prognosis and Dysfunction of Mast Cells in Lung Adenocarcinoma.Cancer Med2026https://conductscience.org/library/papers/42952304PubMed
42,939,938Adaptive Mitochondrial Specialization in Lung Adenocarcinoma: Redox Homeostasis, Hypoxia Adaptation, and Therapeutic Resistance.Antioxidants (Basel)2026https://conductscience.org/library/papers/42939938PubMed
42,875,839PDHA1 Hyperactivation-Mediated Glucose Metabolism Reprogramming Fuels Neutrophil NETosis and Promotes Acute Lung Injury.Adv Sci (Weinh)2026https://conductscience.org/library/papers/42875839PubMed
42,836,261Mitochondrial metabolic-transcriptional axis drives adaptive drug tolerance across major lung cancer subtypes.Front Genet2026https://conductscience.org/library/papers/42836261PubMed
42,458,563The role and application prospects of glycolysis-related non-coding RNAs in lung cancer.J Transl Med2026https://conductscience.org/library/papers/42458563PubMed
42,435,178Targeting Lung Cancer Metabolism: Therapeutic Opportunities and Challenges.Adv Exp Med Biol2026https://conductscience.org/library/papers/42435178PubMed
41,882,242Rosmarinic acid alleviates bleomycin-induced pulmonary fibrosis in mice by activating the Rap1 pathway.Sci Rep2026https://conductscience.org/library/papers/41882242PubMed
41,877,819Targeting ICMT: A promising strategy in cancer treatment (Review).Oncol Lett2026https://conductscience.org/library/papers/41877819PubMed
41,826,648Metabolic networks in the tumor microenvironment: roles of amino acid and lipid metabolism pathways in cancer progression and therapy.Exp Mol Med2026https://conductscience.org/library/papers/41826648PubMed

1 to 10 of 35

See all 35 cited by

Genes32

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ANXA5308PubTator's text mininghttps://conductscience.org/library/genes/308NCBI Gene
CEBPA1,050PubTator's text mininghttps://conductscience.org/library/genes/1050NCBI Gene
CEBPB1,051PubTator's text mininghttps://conductscience.org/library/genes/1051NCBI Gene
CPT1B1,375PubTator's text mininghttps://conductscience.org/library/genes/1375NCBI Gene
CPT1C126,129PubTator's text mininghttps://conductscience.org/library/genes/126129NCBI Gene
CTNNB11,499PubTator's text mininghttps://conductscience.org/library/genes/1499NCBI Gene
DLD1,738PubTator's text mininghttps://conductscience.org/library/genes/1738NCBI Gene
EGFR1,956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
GCLC2,729PubTator's text mininghttps://conductscience.org/library/genes/2729NCBI Gene
GLS2,744PubTator's text mininghttps://conductscience.org/library/genes/2744NCBI Gene

1 to 10 of 32

See all 32 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36970205

GET https://conductscience.org/api/papers/v1/36970205/references?page=2

API referenceFor AI assistants